Pay in 4 interest-free payments of $5.33 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
published in Diabetes, Obesity and Metabolism examined data from 52 randomized controlled trials involving over 75,000 participants treated with GLP-1 receptor agonists
Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medications originally developed to manage type 2 diabetes and, more recently, approved for chronic weight management
The mechanism is not fully understood, but it may relate to reduced caloric intake, altered glucose metabolism, or direct central nervous system effects
However, it remains under investigation whether these benefits are directly due to the GLP-1 agonists or a result of the weight loss they facilitate
For example, semaglutide has FDA-approved cardiovascular benefits for certain patients, while tirzepatide is also approved to treat obstructive sleep apnea in adults with obesity
US$ 20.09
US$ 22.77
US$ 25.79
US$ 25.69
US$ 21.54
US$ 26.13
US$ 28.41
US$ 25.20
US$ 29.15
US$ 25.17
